Chemomab Therapeutics (CMMB) Return on Invested Capital (2021 - 2023)

Chemomab Therapeutics (CMMB) has 3 years of Return on Invested Capital data on file, last reported at 0.01% in Q3 2023.

• For the quarter ending Q3 2023, Return on Invested Capital rose 1.0% year-over-year to 0.01%; the trailing twelve-month figure through Sep 2023 stood at 0.01% (up 1.0% YoY), and the FY2022 full-year result was 0.01%, changed N/A from the prior year.
• Return on Invested Capital for Q3 2023 stood at 0.01%, up from 0.01% in the prior quarter.
• Across five years, Return on Invested Capital topped out at 0.01% in Q3 2023 and bottomed at 0.0% in Q4 2021.
• The 3-year median for Return on Invested Capital is 0.0% (2022), against an average of 0.0%.
• Peak annual rise in Return on Invested Capital reached 1 bps in 2022, while the deepest fall reached 0 bps in 2022.
• A 3-year view of Return on Invested Capital shows it stood at 0.0% in 2021, then soared by 248 bps to 0.0% in 2022, then jumped by 219 bps to 0.01% in 2023.
• The last three Return on Invested Capital figures came in at 0.01% (Q3 2023), 0.01% (Q2 2023), and 0.01% (Q1 2023), per Business Quant data.

Peer Comparison